I-Mab Logo
  • Investors
  • Careers
  • Contact
  • 简体中文
  • About
    Who We Are

    A global innovative biotech company

    Value Creation

    Laser-focused on delivering innovative therapies to patients in need

    Leadership Team

    A world-class global leadership team

    People & Culture

    People are the cornerstone of our success

    Commitment to ESG

    Committed to the highest environmental, social and governance standards

  • Innovation
    Science

    Our cutting-edge science focuses on fine-tuning the immune network in cancer

    Publications & Presentations

    A compilation of our latest publications and presentations

    Operations

    An integrated research, development, manufacturing and commercialization strategy

  • Products
    Product Pipeline

    We have an innovative and advanced immuno-oncology clinical pipeline

    Clinical Trials

    We work closely with global investigators to carefully conduct and monitor clinical studies

  • Partnerships
  • News & Events
    News

    Our Latest News

    Events

    Our Latest Events

I-Mab Logo
  • About
    • Who We Are
    • Value Creation
    • Leadership Team
    • People and Culture
    • Commitment to ESG
  • Innovation
    • Science
    • Publications
    • Operations
  • Products
    • Product Pipeline
    • Clinical Trials
  • Partnerships
  • News & Events
    • News
    • Events
  • Investors
  • Careers
  • Contact
  • 简体中文

Partner News

  • Press Releases
  • Media Reports
  • Partner News

2021.07.09

ABL Bio Announces Publication of Preclinical Data Demonstrating Safety and Efficacy of ABL503/TJ-L14B, a Novel Anti-PD-L1 X 4-1BB Bispecific Antibody

2021.06.29

NeoImmuneTech Announces First Clinical Trial Application Authorization Received in the EU for its Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo® (nivolumab)

2020.11.09

Genexine and NeoImmuneTech Announce Data Release for their Phase 1/2 Study of GX-I7/NT-I7 (efineptakin alfa) and KEYTRUDA® (pembrolizumab) in patients with Triple-Negative Breast Cancer

2020.06.22

Genexine, “Hyleukin-7 (GX-I7), US clinical trial approval for COVID-19 treatment for mild patients”

Sitemap

  • Home
  • About
  • Innovation
  • Products
  • Partnerships
  • News & Events
  • Investors
  • Careers
  • Contact
  • 简体中文

Follow Us

  • LinkedIn
  • Twitter

Copyright © 2023 I-MAB Biopharma Co., Ltd. All Rights Reserved.

沪ICP备17007960号-2 | 沪公网安备31011502018701号